Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 13/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 13/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 13/20 | 0.56 |
| ▸ | BRD4 | O60885 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14560487 | 0.84 | ADRA1D (0.56) | ADRA1DADRA1AADRA1BBRD4 | |
| SCHEMBL3265469 | 0.77 | BRD4 (0.49) | ADRA1DADRA1AADRA1BBRD4HPGD | |
| SCHEMBL21821578 | 0.76 | BRD4 (0.51) | ADRA1DADRA1AADRA1BBRD4HPGD | |
| SCHEMBL11936213 | 0.76 | BRD4 (0.56) | ADRA1DADRA1AADRA1BBRD4HPGD | |
| SCHEMBL14959525 | 0.73 | BRD4 (0.67) | ADRA1DADRA1AADRA1BBRD4HPGD | |
| SCHEMBL3631486 | 0.73 | KMT2A (0.42) | ADRA1DADRA1AADRA1BTSHR | |
| SCHEMBL3458641 | 0.70 | SIGMAR1 (0.69) | TSHR | |
| SCHEMBL3624380 | 0.70 | CHRM2 (0.48) | ADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL7881576 | 0.68 | MEN1 (0.44) | HPGDMAPT | |
| SCHEMBL7671816 | 0.68 | DRD2 (0.79) | ADRA1DADRA1AADRA1BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4599062-B2 | — | — | 2010-12-15 | — | — | JP | claimed |
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | claimed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | claimed |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | ASTELLAS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | US | claimed |
| JP-2005528361-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1487444-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | Fujisawa Deutschland GmbH (DE) | 2004-12-22 | — | — | EP | claimed |
| WO-2003080054-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | FUJISAWA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | WO | claimed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | claimed |
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | disclosed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | ASTELLAS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | FLT1, VEGFA, FLT4 | ADRA1D 1299/4885ADRA1A 1052/4885ADRA1B 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.